ASCO 2021: IMpassion130 Analysis Identifies Tumor Immune Phenotypes and Molecular Subtypes Most Likely to Respond to Atezolizumab
These hypothesis-generating findings could help direct future therapy, pending validation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.